Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation
Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS,
transplant recipients, and fetuses, are at the highest risk for complications from …
transplant recipients, and fetuses, are at the highest risk for complications from …
Does PTCY increase the risk of infections?
M Mikulska, C Bartalucci, AM Raiola, C Oltolini - Blood Reviews, 2023 - Elsevier
PTCY has been mainly used in haploidentical transplant (haploHSCT), but its use in
matched donors allowed better evaluation of infectious risk conferred separately by PTCY or …
matched donors allowed better evaluation of infectious risk conferred separately by PTCY or …
Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide
A Esquirol, MJ Pascual, M Kwon, A Pérez… - Bone Marrow …, 2021 - nature.com
Severe infections and their attributable mortality are major complications in recipients of
allogeneic hematopoietic stem cell transplantation (alloSCT). We herein report 236 adult …
allogeneic hematopoietic stem cell transplantation (alloSCT). We herein report 236 adult …
[HTML][HTML] Posttransplantation cyclophosphamide-and sirolimus-based graft-versus-host-disease prophylaxis in allogeneic stem cell transplant
R Greco, F Lorentino, S Albanese… - … and Cellular Therapy, 2021 - Elsevier
Post-transplantation cyclophosphamide (PTCy) has emerged as a promising graft-versus-
host-disease (GVHD) prophylaxis in the setting of allogeneic hematopoietic stem cell …
host-disease (GVHD) prophylaxis in the setting of allogeneic hematopoietic stem cell …
Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
M Noviello, F Lorentino, E Xue, S Racca… - Blood …, 2023 - ashpublications.org
Abstract Human herpesvirus 6 (HHV-6) can reactivate after allogeneic hematopoietic stem
cell transplant (allo-HSCT) and may lead to severe symptoms. HHV-6–specific immune …
cell transplant (allo-HSCT) and may lead to severe symptoms. HHV-6–specific immune …
Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis …
GC Irene, E Albert, BV Anna, A Rahinatu… - Bone Marrow …, 2021 - nature.com
Post-transplant cyclophosphamide (PTCy) has become a promising option after allo-SCT,
but infections may be more common than in traditional protocols. We herein report 117 …
but infections may be more common than in traditional protocols. We herein report 117 …
CMV infection and CMV-specific immune reconstitution following haploidentical stem cell transplantation: an update
XH Luo, Y Zhu, YT Chen, LP Shui, L Liu - Frontiers in Immunology, 2021 - frontiersin.org
Haploidentical stem cell transplantation (haploSCT) has advanced to a common procedure
for treating patients with hematological malignancies and immunodeficiency diseases …
for treating patients with hematological malignancies and immunodeficiency diseases …
Bacterial bloodstream infections after allogeneic hematopoietic stem cell transplantation: etiology, risk factors and outcome in a single-center study
J Gill, A Busca, N Cinatti, R Passera, CM Dellacasa… - Microorganisms, 2023 - mdpi.com
Background—Allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients are
subject to major risks for bacterial bloodstream infections (BSIs), including emergent …
subject to major risks for bacterial bloodstream infections (BSIs), including emergent …
Post-transplantation cyclophosphamide is associated with increased bacterial infections
C Ustun, M Chen, S Kim, JJ Auletta… - Bone marrow …, 2024 - nature.com
Post-transplant cyclophosphamide (PTCy) is increasingly used to reduce graft-versus-host
disease after hematopoietic cell transplantation (HCT); however, it might be associated with …
disease after hematopoietic cell transplantation (HCT); however, it might be associated with …
Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality
JL Ramdial, RS Mehta, RM Saliba, AM Alousi… - Bone marrow …, 2021 - nature.com
Despite low nonrelapse mortality (NRM) at day 100 after allogeneic hematopoietic cell
transplantation (HCT), NRM at 1 year remains substantial. In this study, we retrospectively …
transplantation (HCT), NRM at 1 year remains substantial. In this study, we retrospectively …